United States: New York is facing a concerning surge in the spread of Candida auris, a drug-resistant superbug posing a potential fatality risk of approximately 60% for those infected.
The state of New York is currently grappling with an alarming outbreak of Candida auris, a superbug resistant to drugs, which has the potential to be fatal for about 60% of individuals who contract it.
Health experts have observed that the majority of cases across the United States have been concentrated in New York.
Cases of this deadly fungal infection continue to rise in various parts of New York.
The US Centers for Disease Control and Prevention has classified Candida auris (C auris) as an “urgent threat,” causing significant concern among health professionals due to its deadly spread.
According to reports from the New York Post, the fatality rate associated with this superbug in the state is around 60%.
Moreover, health authorities have noted a concerning trend of a tripling in the number of cases resistant to echinocandins, the primary antifungal medication recommended for treating C. auris infections.
It’s worth noting that C. auris primarily affects individuals who are already very sick, have invasive medical devices, or spend extended periods in healthcare facilities.
New York ranks among the top three states most affected by this superbug, with 326 reported cases, trailing behind Nevada and California.
Dr. Meghan Lyman, an epidemiologist with the CDC, emphasized the need for continued surveillance, improved diagnostic capabilities, and strict adherence to infection prevention measures to combat the rapid spread of C. auris.
The spread of Candida auris is facilitated through contact with contaminated surfaces or equipment and direct physical contact with infected individuals.
Symptoms of infection include swallowing difficulties and a burning sensation.